Merck (MRK) has done relatively well since the last time I checked on the prospects for the shares (being the end of October) as they traded at similar levels as today. Shares were under pressure in October despite a pick-up in sales of Keytruda. Sales of non-Keytruda drugs were under pressure as Keytruda would not be submitted for treatment of NSCLC in Europe.
Continued growth of Keytruda now makes its additional sales contribution more than offset declines at the other drugs. I am happy with my small holding as sequential improvements continue to drive top line sales growth, setting Merck up for another year of growth in 2018.
Holding A True Blockbuster In The Making
Merck has a very long history of developing drugs, which has had a huge impact on the pharmaceutical industry and society at large, as these discoveries and big sales have come and gone in waves over the past decades, although true, long-term investors have made a killing on the shares.

